As the kidney helps clear several polypeptide hormones, plasma leptin may accumulate in end-stage renal disease. 2. Plasma immunoreactiveleptinwas measured in four groups of subjects: haemodialysis, continuous ambulatory peritoneal dialysis and renal transplant patients and a group of healthy controls. Leptin was also measured before and after a single dialysis session.
3.
There was a strong correlation between plasma immunoreactive leptin and body mass index in all groups except female haemodialysis patients. Leptin was higher in females than in males in all groups when controlled for body mass index. Mean plasma leptin [mean (SD)] was significantly higher in all renal groups [haemodialysis, 15.1 (3.6) ng/ml; continuous ambulatory peritoneal dialysis, 25.4 (4.3) ng/ml; transplants, 11.6 (2.6) ng/ml] compared with controls [5.3 (2.3) ng/ml]. There was a significant difference in the regression equations relating leptin and body mass index (dialysis > transplants > controls), even when controlled for gender. Leptin correlated modestly with serum creatinine in non-dialysis subjects. Plasma leptin immunoreactivity was slightly reduced by haemodialysis, but postdialysis leptin was still significantly higher than that found in controls. 4. Chromatographic characterization of the high level of leptin immunoreactivity found in haemodialysis subjects showed a single elution peak corresponding to that of the highly purified human leptin standard. 5. In conclusion, leptin is higher than expected for body mass index in end-stage renal disease. Hyperleptinaemia could contribute to the anorexia and poor nutritional status commonly seen in renal failure.
INTRODUCTION
Malnutrition, primarily due to poor food intake, is common in dialysis patients. Anorexia is one of the symptoms of uraemia but is only partially corrected by dialysis [1-61. The kidney plays an important role in the disposal of several circulating peptides, including many hormones, such as insulin, glucagon, growth hormone and parathyroid hormone, with renal extraction accounting for 30-80% of their metabolic clearance rates [7, 81 . Leptin is a 16 kDa adipocyte-derived hormone which is thought to be a key regulator of food intake and body weight [9-111. In animals and humans, circulating leptin levels are increased in obesity and reduced by fasting . The kidney has recently been reported to contribute to the clearance of plasma leptin from the circulation in rats [15] . Little is known about the clearance of leptin from plasma in humans. The increase in plasma concentration of several low-molecularweight proteins in renal failure is well described [7, 8, 161 . We tested the hypothesis that alterations in plasma leptin concentration might be present in renal failure in humans, and could therefore potentially contribute to the anorexia and poor nutritional status seen in end-stage renal disease. Plasma immunoreactive leptin was measured in patients undergoing regular dialysis and compared with both a healthy control group and a group of renal transplant recipients. Immunoreactive leptin was also measured before and after a single haemodialysis (HD) session. Since plasma immunoreactivity may consist of partially degraded hormone fragments [7, 81, circulating leptin immunoreactivity was characterized by gel-filtration chromatography.
METHODS

Subjects
Plasma immuoreactive leptin was measured in 100 renal patients and 29 control subjects. All subjects gave verbal informed consent. Known diabetics were excluded. Control subjects all had a normal serum creatinine concentration, had not undergone any recent change in body weight or dietary habit and were not taking any medication. Renal subjects comprised three groups. Fifty-five subjects had end-stage renal disease and were either on regular maintenance HD (n = 36) or continuous ambulatory peritoneal dialysis (CAPD, n = 19). Forty-five subjects were renal transplant recipients with varying degrees of renal impairment. All HD subjects received three sessions of dialysis per week for between 3 and 5 h (median 4 h) using bicarbonate-buffered dialysate and haemophan membrane dialysers (Cobe Centrysystem 400 or 500HG, Gambro GFS Plus 12 or 16). They had been dialysis-dependent for a median of 22 months (range 2-333 months). CAPD subjects were on three to five exchanges of between 1.5 and 2.5 litres of low-calcium dialysate per day and had been dialysis-dependent for a median of 24 months (range 3-36 months). Adequacy of dialysis is routinely assessed with formal urea kinetic modelling every 2months in HD patients, and at three to six monthly intervals in CAPD patients. The dialysis prescription is adjusted to achieve a total KTW (the product of the dialyser urea clearance and treatment time normalized to the volume of distribution of urea) > 1.0 in HD subjects and > 1.7 in CAPD subjects. The mean (SD) weekly total K T N was 1.52 (0.38) in HD subjects and 2.03 (0.36) in CAPD subjects. Body mass index (BMI) was calculated using 'dry weight' in dialysis-dependent subjects. Patients were also categorized according to steroid and antihypertensive treatment. Subjects categorized as on steroids had been on regular prednisolone for at least 7 days [median daily prednisolone dose: HD, 6.5mg (range 2.5-15mg, n=12); CAPD, 6mg (range 2.5-30 mg, n = 4); renal transplants, 7.5 mg (range 2.5-17.5 mg, n = 33)]. Patients described as hypertensive had been on regular treatment with one or more antihypertensive agent (beta adrenergic blocker, alpha adrenergic blocker or calcium antagonist).
Laboratory methods
Non-fasting blood was taken with informed consent from all subjects and plasma was stored at -20°C until analysis. Plasma leptin concentration was measured with a human RIA (Linco Research, St Charles, MO, USA.). The assay uses purified human leptin as standard and a rabbit polyclonal antibody to highly purified recombinant human leptin, details of which have recently been published [17] . The detection and upper limits of this assay were 0.5 and 100 ng/ml respectively. The intra-assay coefficient of variation ranged from 3 . 4 4 3 % with an inter-assay coefficient of variation between 3.6 and 6.2% [17] . Samples with levels above the upper limit of the assay were repeated in duplicate after dilution with assay buffer. Serum creatinine was determined by the alkaline picrate (Jaffe) reaction Three pooled plasma samples from HD subjects (plasma immunoreactive leptin concentration and BMI of the subjects were 167, 142 and 134ng/ml, [181. and 23.1, 23.2 and 35.9 kg/m2 respectively), and samples of the human leptin standard supplied with the RIA kit, were fractionated by Sephadex G-100 superfine column chromatography. The elution coefficient (Kav) was calculated according to Laurent and Killander [19] . The positions of the void volume (Kav = 0) and the total volume (Kav = 1) were determined by the inclusion of Dextran Blue and Na1251 respectively. Fractions eluting between the void and bed volumes were assayed for immunoreactive leptin as previously described [20] and the elution position compared with that of human leptin standard (Linco Research).
Statistical methods
Plasma leptin concentration, age and BMI were not normally distributed within the samples studied. Data were therefore logarithmically transformed and geometric means (SD) are presented throughout. Differences between means of continuous variables were analysed with a one-way analysis of variance together with the Bonferroni adjustment for multiple group testing. Linear correlation analyses were used to describe the association between log-transformed plasma leptin levels and BMI or serum creatinine. Analysis of covariance was used to determine the relationship between plasma leptin and BMI in the different renal groups. Multiple linear regression was used to identify the independent effects of variables associated with variations in leptin concentrations. As the change in plasma leptin concentration after dialysis was not normally distributed, the matched, two sample, Wilcoxon rank sum test was used to compare differences between paired median plasma leptin concentrations from before and after a single dialysis session.
All statistical analyses were performed using the Stata Program Windows Version 4.0 for PC. Significance was considered to be P<0.05.
RESULTS
The clinical characteristics of the study subjects are shown in Table 1 . There was a strong positive correlation between log leptin concentration and BMI, which remained significant for all renal groups except female patients receiving HD (Table 2) . In all groups, leptin levels varied widely between subjects. The mean (SD) plasma leptin concentration was significantly higher in females than in males when all subjects were compared together E18.3 (3.4) compared with 8.5 (3.0) ng/ml, P<0.0005], within the control group subjects [7.7 (2.0) compared with 3.1 (2.2) ng/ml, P<0.005], and in the renal transplant subjects [26.0 (2.4) compared with 8.6 (2.3) ng/ml, P < 0.0005]. This sexual dimorphism of mean leptin concentration was not significant for the HD or CAPD subjects ( Table 3 ). The equations of the regression lines relating log leptin concentration and BMI were, however, significantly different in females than in males in all subjects together (P<O.OOl) and for each individual subject group (Fig. 1) . Therefore, when controlled for BMI, the reported sexual dimorphism in leptin concentration is preserved in end-stage renal disease. The effect of renal failure on mean plasma leptin levels was determined. The mean plasma leptin concentration was significantly higher in all the renal groups [HD 15.1 (3.6) ng/ml, P<O.OOl; CAPD 25.4 (4.3) ng/ml, P< 0.001; transplant 11.6 (2.6) ng/ml, P<0.05] compared with the controls [5.3 (2.3) ng/ml]. These differences remained significant when males and females were analysed separately [female HD 20.8 (3.5) ng/ml, P <0.05; female CAPD 47.1 (4.2) ng/ml, P < 0.005; female transplant 26.0 (2.4) ng/ml, P<0.05, compared with female controls 7.7 (2.0) ng/ml; male HD 11.1 (3.6) ng/ml, P<O.Ol; male CAPD 14.5(3.7) ng/ml, P<O.Ol; male transplant 8.6 (2.3) ng/ml, P < 0.05, compared with male controls 3.1 (2.2) ng/ml]. Regression equations relating log leptin concentration and BMI were compared according to renal status. There was a significant difference in this relationship in all renal groups when compared with the control group, and in the dialysis-dependent subjects when compared with the renal transplant subjects (Fig. 2) . Plasma leptin concentration for a given BMI therefore differs significantly depending on renal group status (dialysis > transplant > controls subjects). These differences remained when controlled for gender.
Log leptin concentration correlated with serum creatinine in non-dialysis subjects (r = 0.33, P<0.005, R2 = 0.11; n = 74). This relationship was still significant after controlling for gender and BMI, and was particularly strong for female non-dialysis subjects (r = 0.67, P<O.OOl, R2 = 0.45; n = 28). Dialysis-dependent subjects were removed from the analyses as serum creatinine is no longer a good predictor of renal function in this group. There was, however, no significant relationship between plasma leptin concentration and residual renal function in either the HD or the CAPD subjects when controlled for gender and BMI. The transplant recipi- The mean plasma leptin levels were similar when individual groups were compared according to antihypertensive treatment status (Table 3) . No attempt was made to analyse leptin levels further according to drug class, as many of these patients were on multiple therapy. Leptin levels were measured in 39 patients before and after a single dialysis session. Median plasma leptin levels were found to be reduced by HD (median pre-dialysis compared with post-dialysis leptin concentration 16.6 compared with 14.2 ng/ml, Pt0.05, estimated median change in leptin = 1.5 ng/ ml, 95% confidence interval 0.1-4.2 ng/ml for difference between paired medians). However, the mean post-dialysis leptin concentration was still significantly higher than that found in control subjects [16.7 (4.0) compared with 5.3 (2.3) ng/ml, P<O.OOl]. No significant correlation was observed between the urea reduction ratio and the plasma leptin reduction ratio (HD subjects), or between plasma leptin concentration and dialysis adequacy, as assessed by total KT/V (HD or CAPD subjects).
Chromatographic characterization of the high plasma leptin immunoreactivity found in HD subjects showed that the majority of leptin immunoreactivity eluted in a position that corresponded to that of the recombinant highly purified human leptin standard supplied in the assay kit ( Figure 3) .
DISCUSSION
There was an overall strong correlation between leptin and BMI, consistent with previous reports [ l l , 14, 15, [21] [22] [23] . This relationship was significant in all renal categories except female HD patients. Gender is now recognized to make a significant independent contribution to the prediction of plasma leptin levels over and above the differences in percentage body fat [21, 22, 241 . It is thought that sex hormones may contribute to the observed gender difference in plasma leptin concentration [21, 241 . As dysfunction of the hypothalamic-pituitary-gonadal axis is common in the dialysis patient population [25], we compared mean immunoreactive leptin levels according to gender and renal status. Although it appeared that this gender dichotomy in mean plasma leptin concentration was lost in the dialysis-dependent patients, leptin levels were in fact higher in females than in males in all groups when controlled for BMI. Much of our observed difference between the regression lines for males and females could, however, still be attributed to the greater percentage of body fat in females for a given BMI (Fig. 1) .
Malnutrition is common in end-stage renal disease and is associated with increased morbidity and mortality [2-51. We have found that leptin levels are higher in dialysis-dependent subjects compared with transplant patients and control subjects when controlled for gender and BMI. Subjects with end-stage renal failure are reported to have a lower percentage body fat than control subjects [26] . It is unlikely, therefore, that the higher leptin levels found in the dialysis subjects when controlled for BMI is due to a higher percentage body fat, and is likely to represent either a decreased plasma clearance and/or an increased production of leptin in end-stage renal disease.
There was a modest correlation between plasma leptin and serum creatinine concentration. There are a number of possible explanations for the apparent lack of a strong correlation between leptin and serum creatinine. Cumin et al. 1151 recently found that bilateral nephrectomy reduced the systemic clearance of exogenous leptin by 81% in rats, but bilateral ureteral ligation, a procedure undertaken to assess the contribution of glomerular filtration, only reduced the systemic clearance by 30%. Although this discrepancy could be due to failure of ureteral ligation to completely disrupt glomerular filtration, it may be that leptin is actively transported into the tubular fluid [15] . Filtered proteins are taken up by proximal tubular epithelial cells and hydrolysed, the catabolic products are then returned to the circulation with negligible amounts detectable in the urine under normal conditions [7, 81. This renal catabolism of filtered peptides contributes to an important fraction of their total metabolic clearance. Renal metabolic processes are not necessarily affected by disease in direct proportion to changes in glomerular filtration. It is also possible that the uraemic state per se may impair extrarenal metabolism of leptin or interfere with the regulation of its synthesis or secretion.
Although the renal subjects were older than the control group in this study, it has been reported that there is either no, or an inverse, correlation between plasma leptin concentration and age after adjustment for body fat content [13, 20, 211 . The finding of a higher plasma leptin concentration in the renal subjects compared with the younger controls is therefore perhaps more significant. We found no correlation between leptin and age within the groups when they were analysed individually.
Dialysis and renal transplant patients are often on multiple drug therapies, including steroids, antihypertensive agents, immunosuppressants and recombinant human erythropoietin, some of which may affect leptin production. Indeed, steroids have been found to increase leptin mRNA expression and protein production in vitro and more recently in vivo . When subjects within each group were compared according to their steroid status, there was no significant difference in the mean leptin concentration between subjects on regular prednisolone and those not taking steroids. When the mean plasma leptin concentration was compared between the different groups after the exclusion of subjects on regular oral steroids, both categories of dialysis patients still had a significantly higher mean leptin concentration than the control subjects, although the difference between the transplant and control subjects was no longer significant. It is therefore unlikely that the presence of steroids confounded the finding of hyperleptinaemia in end-stage renal failure. Plasma leptin levels were also unaffected by the categorization into presence or absence of antihypertensive drug therapy within the different groups. However, many of the subjects were on several different antihypertensive agents and this finding does not exclude the potential effect of individual agents on leptin production in vivo. In addition, it is possible that any differences in plasma leptin concentration due to steroid or antihypertensive treatment were obscured by both the small number of subjects and the disproportionate numbers of males and females within some of the subgroups analysed.
There appears to be an interaction between leptin and the immune and haematopoietic systems [30, 311. Since the availability of recombinant human erythropoietin in the treatment of renal anaemia, dialysis patients have often reported improved appetite as well as increased physical capacity [l] . To what extent, if any, body composition and leptin production is modified by such treatment remains to be determined.
Anorexia is one of the symptoms of uraemia, but is only partially corrected by dialysis. Transport of molecules across a dialyser membrane in conventional HD is predominantly diffusive, dependent on the molecular weight and concentration gradient of the solute across the dialyser membrane as well as on the characteristics of the membrane itself [31] . Leptin levels were reduced by HD, but remained significantly higher than in the control subjects. Even if the majority of leptin circulates in the unbound form in renal failure, it is still a relatively large molecule (molecular weight 16 kDa) compared with creatinine (113 Da) and vitamin B12 (1355 Da). Knowing the characteristics of the dialysis membrane used in the Renal Dialysis Unit at the Hammersmith Hospital (haemophan), one would not expect leptin to be cleared to a significant degree, even at high blood flow rates. High-flux synthetic membranes, however, have comparatively low diffusive resistance and greater clearances of larger solutes can be achieved [32] . Interestingly, Lindsay et al. [33] reported that the switch from a cellulosebased to a synthetic dialysis membrane increased the protein intake of HD patients, as reflected by a change in their protein catabolic rate [33] . It remains to be seen whether these high-flux synthetic membranes can actually clear leptin more effectively.
Since plasma immunoreactivity may consist of partially degraded hormone fragments [7, 81 , circulating leptin immunoreactivity was characterized by gel-filtration chromatography. Immunoreactive leptin eluted in a single peak which corresponded in position to that of the recombinant highly purified human leptin standard. Leptin has, however, been reported to circulate in both free and bound forms in the human circulation, the relative proportions of which appear to be modulated by fasting and obesity [34, 351. We were unable to demonstrate proteinbound leptin in plasma from the HD subjects studied, possibly due to differences in the methodology applied in the chromatographic technique. However, protein binding is recognized to be altered by renal impairment, due to an increase in the number of acidic compounds that compete for binding sites on albumin and other plasma proteins [36] . If free leptin is bioactive, then a high level of circulating free leptin in renal failure would be of particular pathophysiological significance, even if its central anorectic effect were attenuated somewhat by the putative saturable transport into the cerebrospinal fluid [37] .
In conclusion, we have found that leptin levels are increased in end-stage renal disease when controlled for gender and BMI. Leptin levels are reduced by HD, but still remain significantly higher than controls. Hyperleptinaemia could therefore potentially contribute to the anorexia and poor nutritional status seen in end-stage renal failure.
